Spitalul Clinic De Psihiatrie Prof.Dr.Alexandru Obregia — Clinical Trial Site

40 Registered trials

59 Currently recruiting

Organisation

Spitalul Clinic De Psihiatrie Prof.Dr.Alexandru Obregia

Location

Bucharest, Romania

Identifier

ORG-100031383

Address

Strada Argeselu Nr 8, 040874, Romania

Departments

#40767: Pediatric Neurology
#563: Sectia Neurologie Pediatrica
0111: Pediatric Neurology
3021: Pediatric Neurology
9th Department Clinical Psychiatry
Centrul de Sanatate Mintala
Centrul de Sanatate Mintala Spitalul Clinic De Psihiatrie
Clinical Department of Paediatric Neurology
Clinical Psychiatry9
Mental Health Center
n.a.
Neurology
Pediatric Psychiatry
Psihiatrie
Psihiatrie Clinica III
psihiatry
Psychiatry
Psychiatry Department
Psychiatry I Clinical Department
Psychiatry IX
Psychiatry IX Clinical Department
Sectia Cinica Psihiatrie 9
Sectia Clinica II
Sectia Clinica III- Psihiatrie adulti
Sectia Clinica IX
Sectia Clinica Neurologie Pediatrica
Sectia Clinica Psihiatrie III
Sectia Clinica Psihiatrie XII
Sectia Clinica Psihiatrie XV
Sectia I Psihiatrie Adulti
Sectia XII Psihiatrie Adulti

Clinical trials at this site (40)

Search interface

A phase 3 trial of brexpiprazole once-weekly (QW) formulation in patients with acute schizophrenia Recruiting

2022-500583-36-00 Acute Schizophrenia 5 2024-07-01
A study to see how well KarXT is tolerated and how well tolerated it is when taken for long time in participants with psychosis associated w… Recruiting

2023-504151-27-00 Psychosis associated with Alzheimer’s Disease 5 2024-05-09
A Clinical trial to evaluate the efficacy of vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia. (EVOLU… Recruiting

2023-507372-42-00 Schizophrenia 4 2021-09-20
A study to learn about the safety of long-term treatment with brivaracetam in children and young adults with childhood or juvenile absence e… Ended

2023-508095-11-00 Childhood Absence Epilepsy 5 2024-11-27
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and Adolescents with Relapsing-Remitting Mu… Ended

2023-506516-40-00 Relapsing-Remitting Multiple Sclerosis 5 2022-02-11
A two-year, double-blind, randomized, multicenter, active controlled Core Phase study to evaluate the safety and efficacy of fingolimod admi… Ended

2023-507556-68-00 Multiple Sclerosis 5 2013-07-26
A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in … Ended

2024-511057-22-00 Major Depressive Disorder (MDD) with Moderate-to-severe 5 2024-12-04
Ecopipam Tablets to Study Tourette’s Disorder in Children, Adolescents and Adults (D1AMOND) Ended

2023-503494-38-00 Tourette’s Disorder 5 2023-07-20
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects with Schizophrenia Ended

2023-508433-14-00 Schizophrenia 5 2022-09-30
A study to test long-term safety of Iclepertin in people with schizophrenia who took part in a previous CONNEX study Ended

2024-511560-93-00 Schizophrenia 5 2022-03-29
A study to learn if brivaracetam works and is safe in children and young adults 2 to 25 years of age with childhood absence epilepsy or juve… Ended

2023-510428-55-00 Childhood Absence Epilepsy Juvenile Absence Epilepsy 10 2022-03-10
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS2) Ended

2023-506724-85-00 Migraine 5 2020-11-19
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS1) Ended

2023-506253-38-00 Migraine 5 2020-11-09
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia Ended

2022-502233-25-00 Schizophrenia 5
A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label… Ended

2022-503006-20-00 Acutely Psychotic Patients with Schizophrenia 10
A Double-Blind, Oral, Placebo-Controlled, Multiple-Dose, Parallel, Randomized Study to Evaluate Efficacy and Safety of Endoxifen in Bipolar … Ended

2024-511829-57-00 Bipolar I Disorder 5